A cost analysis of sorafenib for desmoid tumors
| العنوان: | A cost analysis of sorafenib for desmoid tumors |
|---|---|
| المؤلفون: | Michael S Johns, William T Merritt, Lori Rhodes, Candice N Ford, Mark Thompson, William M Lee, Yarrow Sheldon, Nicholas J Petrelli, Gregory J Tiesi |
| المصدر: | Journal of Oncology Pharmacy Practice. 29:663-668 |
| بيانات النشر: | SAGE Publications, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | 615: Pharmakologie und Therapeutik, Oncology, Cost analysis, Pharmacology (medical), Desmoid tumor, Sorafenib, 616: Innere Medizin und Krankheiten |
| الوصف: | Introduction A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment. Utilizing these trial data, we performed a cost analysis of sorafenib efficacy through two years of treatment. Methods Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day). Annual costs per progression and objective response were calculated. Radiologic progression and response were defined using RECIST criteria. Patients with disease progression were separately analyzed in two groups: both clinical and radiologic (CAR), and radiologic alone. Results 84 previously randomized patients were analyzed (placebo: 35, sorafenib: 49). At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year. Two-year ARR was 17.5% with NNT 5.7 and estimated costs $1,285,052. Sorafenib patients experienced improved RECIST partial response rates at 1 and 2 years of 14.7% and 14.3%, with NNT 6.8 and 6.9, and costs of $766,938 and $1,556,433; respectively. Conclusion For the treatment of desmoid tumors, Sorafenib led to improved PFS, but at a significant cost per patient. Favorable RECIST outcomes were less likely and costlier. Patients should be informed of possible benefits of treatment versus potential financial burden. |
| تدمد: | 1477-092X 1078-1552 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::665b3fcc992c6232a381aca585af8b46 https://doi.org/10.1177/10781552221077927 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....665b3fcc992c6232a381aca585af8b46 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1477092X 10781552 |
|---|